Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, ImmunityBio Inc’s stock clocked out at $2.85, up 3.26% from its previous closing price of $2.76. In other words, the price has increased by $3.26 from its previous closing price. On the day, 10.77 million shares were traded. IBRX stock price reached its highest trading level at $2.97 during the session, while it also had its lowest trading level at $2.79.
On March 06, 2025, H.C. Wainwright started tracking. The Stock assigning a Buy rating and target price of $8. On January 10, 2025, BTIG Research started tracking. The Stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2693975552 and an Enterprise Value of 3383914752. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 47.60. Its current Enterprise Value per Revenue stands at 59.786 whereas that against EBITDA is -12.577.
Stock Price History:
The Beta on a monthly basis for IBRX is 0.16, which has changed by -0.19034094 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $7.48, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of. The Stock is 11.20%, while the 200-Day Moving Average is calculated to be -0.01%.
Shares Statistics:
It appears that IBRX traded 8.64M shares on average per day over the past three months and 12729830 shares per day over the past ten days. A total of 915.63M shares are outstanding, with a floating share count of 98.33M. Insiders hold about 89.60% of the company’s shares, while institutions hold 13.19% stake in the company. Shares short for IBRX as of 1756425600 were 75307294 with a Short Ratio of 8.71, compared to 1753920000 on 77068923. Therefore, it implies a Short% of Shares Outstanding of 75307294 and a Short% of Float of 25.869999999999997.
Earnings Estimates
. The Stock of ImmunityBio Inc (IBRX) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.38 and -$0.51 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.28, with 3.0 analysts recommending between -$0.26 and -$0.3.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $31.88M. It ranges from a high estimate of $38.11M to a low estimate of $27.5M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $6.11MFor the next quarter, 5 analysts are estimating revenue of $35.29M. There is a high estimate of $47.64M for the next quarter, whereas the lowest estimate is $30M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $128.7M, while the lowest revenue estimate was $100.44M, resulting in an average revenue estimate of $110.16M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $221.5M in the next fiscal year. The high estimate is $279.4M and the low estimate is $140.83M.
